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Increasing antibiotic resistance warrants therapeutic alternatives. Here we 
investigated the efficacy of bacteriophage-therapy (phage) alone or combined with 
antibiotics against experimental endocarditis (EE) due to Pseudomonas aeruginosa, 
an archetype of difficult-to-treat infection. 
METHODS: 
In vitro fibrin-clots and rats with aortic EE were treated with an anti-pseudomonas 
phage cocktail alone or combined with ciprofloxacin. Phage pharmacology, 
therapeutic efficacy, and resistance were determined. 
RESULTS: 
In vitro, single-dose phage-therapy killed 7 log CFU/g of fibrin-clots in 6 h. Phage-
resistant mutants regrew after 24 h, but were prevented by combination with 
ciprofloxacin (2.5xMIC). In vivo, single-dose phage-therapy killed 2.5 log
 
CFU/g of 
vegetations in 6 h (P < 0.001 versus untreated controls) and was comparable to 
ciprofloxacin monotherapy. Moreover, phage-ciprofloxacin combinations were highly 
synergistic, killing >6 log CFU/g of vegetations in 6 h and successfully treating 64% 
(7/11) of rats. Phage-resistant mutants emerged in vitro but not in vivo, most likely 
because resistant mutations affected bacterial surface determinants important for 
infectivity (e.g. the pilT and galU genes involved in pilus motility and LPS formation).  
CONCLUSION: 
Single-dose phage-therapy was active against P. aeruginosa EE and highly 
synergistic with ciprofloxacin. Phage-resistant mutants had impaired infectivity. 
Phage-therapy alone or combined with antibiotics merits further clinical consideration.  
















The global increase in antibiotic resistance is reviving the need for alternative 
antimicrobial strategies, including phage therapy. This “forgotten cure” was 
developed in parallel to antibiotics during the first half of the 20th century and is still 
commonly used in countries of the former Soviet Union [1]. However, it was not 
developed at large scale in Western countries, and information on phage 
pharmacokinetics/pharmacodynamics (PK/PD), drug interactions, in vivo efficacy, 
and emergence of resistance remains scarce. Phages have been administered by 
various routes, including inhalation for pneumonia (reviewed in [2]), surgical rinsing 
for chronic osteomyelitis [3], and intravenous injection for severe systemic infections, 
such as typhoid fever (reviewed in [4]). However, o ly few studies provide a 
comprehensive picture linking phage pharmacology to antibacterial efficacy [5, 6]. 
Moreover, with few exceptions [6], the emergence of phage resistance is seldom 
addressed, even in recent clinical studies [7-9]. 
Detailed understanding of bacterial resistance to phages is critical if phages were to 
be used more broadly in the clinical setting. Phage-resistant bacteria can result from 
several mechanisms, including modification of cell-surface receptors, restriction-
modification of incoming (foreign) phage DNA, or inter-phage immunity [10]. 
Resistance mutations may arise spontaneously in vitro and are likely to be selected in 
vivo as well [6]. Some mutations may affect LPS (a common phage receptors) and 
impact bacterial fitness or virulence [11-13]. However, other kinds of mutations or 
further mutations restoring virulence cannot be excluded and must be scrutinized. 
The intrinsic bactericidal properties of anti-infective compounds are most reliably 
studied in models of “therapeutic sanctuaries”, where natural host defenses are 
poorly involved. Experimental endocarditis (EE) and experimental meningitis are two 















such models. Experimental meningitis implicates a special anatomical setting where 
drug distribution depends on the blood-brain barrier. In contrast, EE mirrors the 
general situation encountered in many deep-seated infections. Moreover, 
endocarditis pathogens surround themselves with amorphous aggregates of platelet-
fibrin clots in which cellular host defenses cannot penetrate (for review see [14]). 
Thus, the capability of antimicrobials to penetrate into vegetations is a critical issue. 
In the present experiments, we systematically explored the efficacy of a clinically-
used anti-pseudomonas phage cocktail (cocktail PP1131 currently investigated in the 
multicentric Phagoburn clinical trial for treatment of burn-wound infections; 
http://www.phagoburn.eu) in a dual in vitro and in vivo model of experimental 
endocarditis due to P. aeruginosa. 
Phage therapy alone was active both in vitro and in animals with EE. Moreover, it 
was highly synergistic with antibiotics. Although phage-resistant bacteria emerged in 
vitro, they were not detectable in vivo due to fitness alteration in the animal milieu. 
These results suggest that phage therapy alone or combined with antibiotics (in this 
case ciprofloxacin) deserves further consideration for future clinical application. 
 
Results 
P. aeruginosa host range of individual phages composing the PP1131 cocktail. 
The 12 phages contained in the PP1131 cocktail were evaluated for their ability to 
lyse a panel of 33 laboratory and clinical isolates of P. aeruginosa from our own 
collection using spot assays (Supplementary Table 1 and 2). This test showed that 
31/33 (94 %) of the P. aeruginosa isolates were lysed by at least two phages, 
whereas only strains PA7 and 10 were resistant to the 12 phages. The relatedness of 















the 12 phages regarding strain specificity was further evaluated by hierarchical 
cluster analysis based on a binary matrix derived from the spot assay. 
Supplementary Figure 1 indicates that the phages of the cocktail were different from 
each other regarding to their host specificity profiles, thus ensuring coverage of 
multiple strains.  
Of note, spot assays indicate both lysis-from-within (due to productive phage 
infection) and lysis-from-without (due to phage attachment only). Therefore, while 
they assess specificity of phage-bacteria interactions they may underestimate 
genuine productive infectivity. In the present experiments the PP1331 phage cocktail 
achieved productive infection in 28/33 (84%) of the tested strains (Supplementary 
Figure 2). 
 
Activity of the phage cocktail in the in vitro fibrin-clot model. The efficacy of the 
cocktail was tested in fibrin clots simulating endocarditis vegetations [15]. Two P. 
aeruginosa strains were used, namely strain P7, which was not infected by any of the 
cocktail’s phages, and strain CHA which was susceptible to all of them. For resistant 
strain PA7, no phage-induced killing and no in situ phage amplification was observed 
(Figure 1.A). Moreover, physical disintegration of the clots, possibly due to the action 
of bacterial proteases, was observed after 24 h (Figure 1.C). 
In contrast, a significant loss of bacterial viability of approximately 6 logs CFU/g was 
observed after 6 h when CHA-infected clots were challenged with the cocktail (Figure 
1.B, p = 0.0001 compared to the initial bacterial load). Phage-induced killing was 
accompanied by a phage amplification of 5 log PFU/g of clots (p = 0.0001 compared 
to non-infected clots). In addition, phage-induced bacterial killing prevented bacterial-
induced clot disintegration (Figure 1.D), indicating that phages diffused through the 















fibrin meshwork and killed bacteria located inside the clots. Yet, the sharp initial 
phage-induced killing was followed by bacterial regrowth after 24 h (Figure 1.B). This 
regrowth was caused by the development of phage-resistant bacterial mutants and 
was not accompanied by further phage amplification.  
 
Frequency of phage resistance in broth cultures and fibrin clots. In the absence 
of phages, spontaneous resistant mutants occurred at an average frequency of ca. 
10-7, and at ca. 10-8 against the whole cocktail (result not shown) both in batch 
cultures and in fibrin clots after 6 h and 24 h (Supplementary Table3, column 2). In 
contrast, the proportion of phage-resistant bacteria increased sharply after exposure 
to phages due to the replacement of phage-susceptible bacteria by resistant 
subpopulations, i.e. 10-4 at 6 h and 10-2 at 24 h (Supplementary Table S3, columns 5 
and 6).  
 
Prevention of phage resistance using phage-antibiotic combinations. In order to 
prevent the development of phage-resistant subpopulations we attempted to combine 
phages with antibiotics. Combining the phage cocktail with 2.5-times the MIC of 
ciprofloxacin or meropenem inhibited the regrowth of phage-resistant mutants after 
24 h (Figure 2.A and 2.B, dashed dotted lines, respectively). Moreover, the two 
antibiotics were highly synergistic with phages at 24 h, as defined by a ≥ 3 log 
CFU/ml decrease in bacterial viable counts when compared to single phage or 
antibiotic therapy alone. 















Phage pharmacokinetics. The pharmacokinetics of the phage cocktail was 
assessed in the plasma and tissues of non-infected rats with catheter-induced aortic 
vegetations following a single intravenous (i.v.) bolus injection or during continuous 
infusion (Figure 3.A, solid and dashed line, respectively). A high plasma titer (8.5 ± 
1.5 log PFU/ml) was measured 1 h after bolus injection, followed by a continuous 
decrease to 4.9 ± 0.6 log PFU/ml at 24 h (elimination half-life = ca. 2.3 h). In parallel, 
the concentrations of phages in vegetations decreased from 7.5 ± 0.3 to 6.2 ± 0.9 log
 
PFU/g between 6 h and 24 h post administration. A similar tendency was observed in 
the spleen, kidney, liver, lung and brain (elimination half-life = ca. 9 h, Supplementary 
Figure 3). This demonstrated phage diffusion into the organs and delayed phage 
clearance compared to plasma. During continuous infusion, phage titers in plasma 
progressively increased to reach a plateau of 8.5 ± 0.2 log PFU/ml after 6 h, which is 
comparable to the concentration achieved after 1 h following bolus injection. Phage 
concentrations in the vegetations and organs remained high after 24 h (7.4 ± 0.9 log 
PFU/ml, Supplementary Figure 3).  
 
Treatment of EE. Inoculation with 108 CFU of P. aeruginosa CHA induced EE with 
bacterial loads in vegetations of control rats of > 8 log CFU/g 18 h after bacterial 
challenge (Figure 3.B). Administration of the phage cocktail 18 h after bacterial 
challenge by either continuous or bolus injection decreased median vegetation 
bacterial titers by 3.0 and 2.3 log
 
CFU/g, respectively, within 6 h of therapy (Figure 
3.B; p < 0.0001 compared to treatment onset). No significant difference between the 
two routes of administration was observed. Notably, a single bolus injection of 
ciprofloxacin simulating a single oral dose of 750 mg in adults [16] decreased median 
vegetation bacterial titers by 2.6 log CFU/g (Figure 3.B), which was comparable to 















phage therapy. Moreover, the combination of phages with ciprofloxacin was highly 
synergistic, resulting in negative vegetation cultures in 7/11 rats receiving combined 
therapy after 6 h, as compared to 0/28 in phage-alone or ciprofloxacin-alone treated 
groups (Figure 3.B; p < 0.005). Likewise, the residual median vegetation bacterial 
titers of ≤ 2 log CFU/g in the combined therapy group were significantly lower than 
the ≥ 6 log CFU/g titers detected in the monotherapy groups (p < 0.0001).  
 
In situ penetration of phages in valve tissues. Optical microscopy and 
transmission electron microscopy (TEM) were performed on vegetation samples in 
order to visualize the presence and activity of phages inside the vegetations. Figure 4 
presents relevant pictures of these experiments, including intra-vegetation P. 
aeruginosa in untreated rats (Figure 4.A and 4.B), negatively stained phages from the 
cocktail with a capsid size of ca. 70 nm (Figure 4.C), and intra-vegetation lysed 
bacteria in phage treated rats with bacterial ghosts containing phage particles (Figure 
4.D).  
 
Correlation between phage multiplication, antimicrobial activity, and cytokine 
production. In vivo antibacterial activity correlated with phage amplification (ca. 3 log 
PFU/g of vegetations) after both continuous and bolus injection (Figure 3.C). This 
relation was further underlined by the scatter plot presented in Figure 3.D, which 
showed a significant inverse correlation between phage and bacterial concentrations 
in the vegetations (correlation value (r); -0.66, Pearson two tailed correlation test; p = 
0.003). 















Successful phage therapy also correlated with the production of specific inflammatory 
cytokines (Figure 5). Concentrations of IL-1β, IL-6 and TNFα in plasma were 
quantified by Luminex first before inoculation, second before treatment onset, and 
lastly after 6 h of phage therapy in uninfected and infected rats (Figure 5.A). Several 
observations were drawn from these measurements. First, although there were 
trends in cytokine-induction by bacteria and phages alone, these were not statistically 
significant. Second, TNFα levels remained essentially unaltered in all of the groups 
throughout the experiment. Finally, only phages treatment, but not ciprofloxacin, 
significantly increased plasma levels of IL-1β and IL-6 (Figure 5.B). Since 
ciprofloxacin is not bacteriolytic, the increase in IL-1β and IL-6 levels was likely 
related to phage-induced bacterial lysis. 
 
Phage resistance in EE. Since spontaneous phage-resistant mutants occurred at a 
rate of 10-7 in batch cultures and fibrin clots, they were also expected to emerge in 
infected vegetations. To test this assumption, phage-resistant mutants were sought in 
infected valves by plating vegetation extracts directly on agar plates containing pre-
adsorbed phages. Unexpectedly, no phage-resistant mutants could be isolated from 
the infected vegetations either before or after therapy, therefore suggesting that 
phage resistance might result in altered virulence or fitness and interfere with 
successful bacterial survival or growth in vivo. Two resistant isolates recovered from 
fibrin clots, 19/2 and 24/2, which showed different phage resistance patterns, were 
further characterized to verify this hypothesis. Figure 6.A shows that these resistant 
isolates had markedly different phage susceptibility profiles when compared to the 
parent strain. Mutant 24/2 conferred turbid plaques while the mutant 19/2 was 















resistant to 10 of the 12 phages and displayed a melanized (dark colonies) 
phenotype.  
To determine whether these mutants had altered virulence, they were tested for their 
capability to infect sterile vegetations. A single bolus of 108 CFU (i.e. infective dose 
90% (ID 90) of parent strain) led to the infection of < 60 % (p < 0.05) and < 30 % (p < 
0.01) of vegetations for mutants 19/2 and 24/2, respectively (Figure 6.B). Moreover, 
the median bacterial densities in the infected vegetations were significantly lower 
than in rats infected with the parent strain (CHA, 8.9 CFU/g; 24/2, 7.3 CFU/g; and 
19/2, 6.8. p < 0.05) and blood cultures were negative.  
To further investigate the origin of this impaired in vivo infectivity the genomic DNA of 
the parent strain CHA and the two mutants was sequenced, assembled, and 
compared (Figure 7.A). Mutant 24/2 displayed a 15 bp deletion at the 3’ end of the 
pilT gene (Supplementary Figure 4), which encodes an ATPase involved in motility 
[17]. As a result, mutant 24/2 exhibited loss of twitching motility (Figure 7.B). Mutant 
19/2 had a 362 kb genomic deletion encompassing 342 genes. These included the 
galU gene, which is involved in P. aeruginosa LPS core synthesis. galU-deletion was 
shown to be responsible for phage resistance [18]. The resulting absence of O-
antigen and LPS core truncation was confirmed by LPS extraction followed by gel 
electrophoresis (Figure 7.C). Mutant 19/2 also showed a 3-fold decrease in its MIC of 
ciprofloxacin (0.064 vs 0.192 µg/ml for mutant 19/2 and parent CHA, respectively).  
















While phage therapy is a promising alternative to antibiotics against specific and 
difficult-to-treat infections, careful appraisal of its therapeutic potential is an absolute 
prerequisite before clinical application.  
Here we evaluated the in vitro activity of the whole phage cocktail and its individual 
phage components against a panel of independent P. aeruginosa isolates in test 
tubes and in fibrin clots. This revealed the presence of bacterial strains with opposite 
susceptibility profiles, either resistant to all the cocktail’s phages (e.g. strain PA7) or 
susceptible to all of them (e.g. strain CHA). The frequency of spontaneous phage 
resistance mutations of the susceptible strain CHA was found to be of ca. 10-7. This 
predicted that phage resistance would emerge in infected fibrin clots, which contained 
> 108 CFU/g. This was indeed the case. However these approach experiments 
highlighted two additional important facts. First, phages could readily diffuse into clots, 
kill the overwhelming majority of phage-susceptible bacteria in situ, and protect the 
fibrin matrix from bacterial-induced disintegration. Second, combining phages with 
low concentrations of ciprofloxacin or meropenem (2.5 x the MIC) inhibited the 
regrowth of phage-resistant mutants, suggesting potential success of in vivo therapy. 
The in vivo experiments provided further critical information. Regarding PK/PD 
parameters, phages were relatively stable in plasma (elimination half-life of ca. 2.3 h 
following bolus administration) and persisted longer in organs (half-life up to 9 h). 
These values were consistent with those observed in previous work [19] and 
confirmed that phages, whose sizes vary from ca. 50 to 200 nm, can diffuse into 
various body compartments [5, 6, 20]. As a result, phages were able to kill bacteria 
inside valve vegetations and multiply locally by up to 3 log PFU/g within 6 h. Phage-
induced killing correlated with a burst of IL-1β and IL-6. Since cytokine levels were 















measured only at a single time point, the data did not permit extrapolating the 
dynamics of cytokine responses over time. However, the significant increase in IL-1β 
and IL-6 levels in rats treated with phages – as compared to rats treated with 
ciprofloxacin – most likely reflected the release of cell debris by phage-mediated 
lysis. Accordingly, it is known that both cytokines are inducible by LPS [21] and that 
similar results were obtained in EE using a bactericidal phage lysin [22]. 
From a therapeutic point of view, the combination of phages with ciprofloxacin 
exhibited a highly synergistic effect and resulted in 7/11 (64%) negative valve 
cultures within 6 h. This remarkable result has no precedent in antimicrobial therapy 
of EE with virtually any drug or pathogen, and especially not with P. aeruginosa [23-
25]. 
Phage-antibiotic (or PAS) synergism has been formerly reported [26-29]. The 
mechanism of PAS is proposed to result from antibiotic-induced bacterial elongation, 
which may facilitate the access of phages to their bacterial target [29]. However, none 
of the previous PAS studies were done in vivo and none of them demonstrated the 
extensive killing of > 7 orders of magnitude in 6 h reported herein [26-29]. 
Interestingly, phage-resistant subpopulations were readily detected in broth cultures 
and infected clots, but not in vegetations. This suggests that preexisting phage-
resistant mutants might be hampered in vivo, as proposed by others [6, 11, 12, 30, 
31].  
In fact, the mutations that conferred resistance to the phage cocktail came at a great 
physiological cost. The present experiments provide two examples supporting this 
notion. Mutant 24/2 exhibited defective cell motility due to disruption of the pilT gene, 
whose product is an ATPase providing energy for type IV pilus contraction and 
bacterial twitching [17]. Type IV pilus is also a phage receptor and pilus contraction is 















believed to bring the phages closer to the bacterial envelope [32]. Mutant 19/2 had a 
truncated LPS resulting from a large deletion encompassing the galU gene involved 
in the synthesis of the LPS core [18, 33]. LPS can also act as a phage receptor and 
its alteration can confer phage resistance [13]. Both type IV pili and LPS are major 
virulence factors in P. aeruginosa and their mutation can result in attenuated 
virulence [13, 34]. Thus, while these mutations confer resistance to phages, they may 
also decrease fitness in animals, while preserving normal growth in less stringent in 
vitro conditions.  
While these observations are promising regarding phage antibacterial activity, caution 
should be raised as to the use of phage cocktails versus single phage preparations. 
While, phage cocktails provide broader strain coverage than single phages, they also 
carry greater risks of unwanted gene transfer and inter-phage interference. Ideally 
phages should be tailored against their target pathogen and specificity should be 
preferred to exhaustiveness, just like for antibiotic therapy. 
Altogether the present results provide a strong proof-of-concept for phage therapy of 
deep-seated and systemic infections. Moreover they raise the provocative possibility 
that certain infections might be cured by a single phage injection most efficiently 
combined with synergistic antibiotics. Indeed, once locally established phages can 
multiply in situ and do not necessitate further administration.  
















Strains, phage cocktail and antibiotics. A total of 33 P. aeruginosa reference 
strains and clinical isolates from our own clinical strain collection were used in in vitro 
susceptibility determinations (Supplementary Table 1). These isolates were not 
meant cover the diversity of contemporary pseudomonas from our hospitals, but to 
select strains with extreme phenotypes to be tested in the present experiments 
Growth conditions and reagents are given in the supplementary material.  
 
In vitro studies. The host range of the individual phages composing the PP1131 
cocktail was determined using spot or plaque assays [35]. Experiments were done in 
triplicates. Plasma clots were prepared in 96-well microplates, as previously 
described [15]. Phage titers were measured by plaque assays [35]. The activity of the 
phage cocktail was considered bactericidal when it killed ≥ 3 log CFU of the starting 
inoculum in the clot. Details are provided in the supplementary materials. 
 
Animal studies. Experiments were approved by and in adherence with the 
guidelines of the Swiss Animal Protection Law, Veterinary office, State of Vaud. 
Experiments were performed under license number 879.9 and in accordance with the 
regulations of the cantonal committee on animal experimentation of the State of Vaud, 
Switzerland. The production of catheter-induced aortic vegetations and the 
installation of an i.v. line into the superior vena cava, connected to an infusion pump 
to deliver the phage cocktail, were performed in female Wistar rats as previously 
described [16]. Details are provided in the supplementary materials.  
 















Histology. Semi-thin and ultra-thin sections were prepared as described in [36] and 
cut with a Leica Ultracut microtome (Leica Mikrosysteme GmbH, Vienna, Austria). 
Sections were stained for light microscopy using the modified Brown and Brenn 
method, as described in [37]. Ultra-thin sections of 50 nm were stained as described 
in. For phage observation, phage cocktail was adsorbed on copper 200-mesh grid 
coated with Formvar-carbon (EMS) and stained with uranyl acetate. Micrographs 
were taken with a transmission electron microscope FEI CM100 (FEI, Eindhoven, 
tfhe Netherlands) at an acceleration voltage of 80 kV with a TVIPS TemCam-F416 
digital camera (TVIPS GmbH, Gauting, Germany). 
 
Cytokine measurements. The serum inflammatory cytokines IL-1β, IL-6 and TNFα 
were quantified prior to infection (24 h after surgery), prior to therapy (18 h after 
bacterial inoculation) and at sacrifice (6 h after onset of therapy). Plasma was kept at 
-80°C and cytokines titers were using the Biorad Bi o-Plex Rat Cytokine Kit in a 
Luminex 200 system and following manufacturer’s recommendations ( done by MEF; 
University of Lausanne, Switzerland). 
 
Detection and characterization of phage resistance. Phage resistant bacteria 
were isolated from broth cultures, in vitro fibrin clots, and rat vegetations by plating on 
blood agar plates containing 1010 PFU pre-absorbed phages. Resistance rates were 
determined as the number of bacteria growing on plates pre-adsorbed with phages 
divided by the number of bacteria growing on plain plates. In vivo infectivity of phage 
resistant was assessed by inoculating rats with catheter-induced aortic vegetations 
as previously described. Full genomic DNA sequencing was performed by the Center 
for Integrative Genomics (CIG; University of Lausanne, Switzerland) using the Pacific 















Biosciences RSII platform (Pacific Bioscience, Menlo Park, CA). Total DNA was 
extracted using the DNeasy Blood and Tissue kit (Qiagen, Valencia, CA, USA) 
according to manufacturer’s instructions. GenDB [38], BLASTn [39], and BRIG [40] 
were used for genomic analysis. Subsurface twitching motility tests were performed 
as described [41]. LPS was extracted using the iNTRON LPS extraction kit (iNtRON 
biotechnology, Daejeon, South Korea), resolved on NuPAGE 4-12% BisTris gels 
(Invitrogen, Carlsbad, CA, USA), and silver stained according to [42]. Details are 
provided in the supplementary materials. 
 
Notes 
Acknowledgments. We are indebted to Marlyse Giddey, Matthew Parkan, Sara 
Mitri, Glib Mazepa, Shawna McCallin, Jean Daraspe and Gilles Willemen for their 
invaluable technical support and fruitful discussions.  
 
Financial support. This work was supported in part by the Swiss National Research 
Foundation (CR31I3_166124, 310030-143799) (YAQ, JME) and the European 
Commission research grant (FP7-PHAGOBURN) (YAQ). This work was also 
supported by a non-restricted grant from the Loterie Suisse Romande (YAQ). The 
funders had no role in study design, data collection and interpretation, or the decision 
to submit the work for publication. 
 
Potential conflict of interest. Jérôme Gabard is employed by the commercial 
company Pherecydes Pharma as COO. The bacteriophage cocktail PP1131 used in 
this study is produced under license by the company Pherecydes Pharma and used 















in a human clinical trial (Phagoburn, NCT02116010, http://www.phagoburn.eu/). Yok-
Ai Que is co-investigator in the clinical trial Phagoburn, which uses the PP1131 
bacteriophage cocktail.  
 
Correspondence. Please address correspondence to Frank Oechslin, 
Frank.Oechslin@gmail.ch. University of Lausanne, Quartier UNIL-Sorge, Bâtiment 
Biophore, CH-1015 Lausanne, Switzerland.  

















1. Chanishvili N. Phage therapy--history from Twort and d'Herelle through Soviet 
experience to current approaches. Adv Virus Res 2012; 83:3-40. 
2. Abedon ST. Phage therapy of pulmonary infections. Bacteriophage 2015; 5:e1020260. 
3. Lang G, Kehr P, Mathevon H, Clavert JM, Sejourne P, Pointu J. [Bacteriophage therapy 
of septic complications of orthopaedic surgery (author's transl]. Rev Chir Orthop 
Reparatrice Appar Mot 1979; 65:33-7. 
4. Speck P, Smithyman A. Safety and efficacy of phage therapy via the intravenous route. 
FEMS Microbiol Lett 2016; 363. 
5. Chhibber S, Kaur S, Kumari S. Therapeutic potential of bacteriophage in treating 
Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J Med Microbiol 
2008; 57:1508-13. 
6. Pouillot F, Chomton M, Blois H, et al. Efficacy of bacteriophage therapy in experimental 
sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain 
producing CTX-M-15. Antimicrob Agents Chemother 2012; 56:3568-75. 
7. Marza JA, Soothill JS, Boydell P, Collyns TA. Multiplication of therapeutically 
administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 2006; 
32:644-6. 
8. Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a 
therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant 
Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009; 
34:349-57. 
9. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. 
Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J 
Wound Care 2009; 18:237-8, 40-3. 
10. Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nat Rev 
Microbiol 2010; 8:317-27. 
11. lenski RE. Experimental studies of pleiotropy and epistasis in Escherichia coli 
variation in competitive fitness among mutants resistant to virus T4. Evolution 1988; 
42:425-32. 
12. Scanlan PD, Buckling A, Hall AR. Experimental evolution and bacterial resistance: 
(co)evolutionary costs and trade-offs as opportunities in phage therapy research. 
Bacteriophage 2015; 5:e1050153. 
13. Le S, Yao X, Lu S, et al. Chromosomal DNA deletion confers phage resistance to 
Pseudomonas aeruginosa. Sci Rep 2014; 4:4738. 
14. Que YA, Moreillon P. Infective endocarditis. Nature reviews Cardiology 2011; 8:322-
36. 
15. Entenza JM, Haldimann A, Giddey M, Lociuro S, Hawser S, Moreillon P. Efficacy of 
iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant 
Staphylococcus aureus isolates in an in vitro fibrin clot model. Antimicrob Agents 
Chemother 2009; 53:3635-41. 
16. Entenza JM, Vouillamoz J, Glauser MP, Moreillon P. Levofloxacin versus ciprofloxacin, 
flucloxacillin, or vancomycin for treatment of experimental endocarditis due to 
methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents 
Chemother 1997; 41:1662-7. 















17. Mattick JS. Type IV pili and twitching motility. Annu Rev Microbiol 2002; 56:289-314. 
18. Dean CR, Goldberg JB. Pseudomonas aeruginosa galU is required for a complete 
lipopolysaccharide core and repairs a secondary mutation in a PA103 (serogroup O11) 
wbpM mutant. FEMS Microbiol Lett 2002; 210:277-83. 
19. Merril CR, Biswas B, Carlton R, et al. Long-circulating bacteriophage as antibacterial 
agents. Proc Natl Acad Sci U S A 1996; 93:3188-92. 
20. Gorski A, Wazna E, Dabrowska BW, Dabrowska K, Switala-Jelen K, Miedzybrodzki R. 
Bacteriophage translocation. FEMS Immunol Med Microbiol 2006; 46:313-9. 
21. de Bont N, Netea MG, Rovers C, et al. LPS-induced release of IL-1 beta, IL-1Ra, IL-6, 
and TNF-alpha in whole blood from patients with familial hypercholesterolemia: no 
effect of cholesterol-lowering treatment. J Interferon Cytokine Res 2006; 26:101-7. 
22. Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P. Therapeutic effects 
of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. 
Antimicrob Agents Chemother 2005; 49:4789-92. 
23. Papadakis JA, Samonis G, Maraki S, Boutsikakis J, Petrocheilou V, Saroglou G. Efficacy 
of amikacin, ofloxacin, pefloxacin, ciprofloxacin, enoxacin and fleroxacin in experimental 
left-sided Pseudomonas aeruginosa endocarditis. Chemotherapy 2000; 46:116-21. 
24. Bayer AS, Norman D, Kim KS. Efficacy of amikacin and ceftazidime in experimental 
aortic valve endocarditis due to Pseudomonas aeruginosa. Antimicrob Agents 
Chemother 1985; 28:781-5. 
25. Robaux MA, Dube L, Caillon J, et al. In vivo efficacy of continuous infusion versus 
intermittent dosing of ceftazidime alone or in combination with amikacin relative to 
human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. J 
Antimicrob Chemother 2001; 47:617-22. 
26. Ryan EM, Alkawareek MY, Donnelly RF, Gilmore BF. Synergistic phage-antibiotic 
combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol Med 
Microbiol 2012; 65:395-8. 
27. Knezevic P, Curcin S, Aleksic V, Petrusic M, Vlaski L. Phage-antibiotic synergism: a 
possible approach to combatting Pseudomonas aeruginosa. Res Microbiol 2013; 164:55-
60. 
28. Kamal F, Dennis JJ. Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): 
antibiotics stimulate lytic phage activity. Appl Environ Microbiol 2015; 81:1132-8. 
29. Comeau AM, Tetart F, Trojet SN, Prere MF, Krisch HM. Phage-Antibiotic Synergy 
(PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One 
2007; 2:e799. 
30. Scanlan PD, Hall AR, Blackshields G, et al. Coevolution with bacteriophages drives 
genome-wide host evolution and constrains the acquisition of abiotic-beneficial 
mutations. Mol Biol Evol 2015; 32:1425-35. 
31. Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli 
diarrhoea in calves by means of bacteriophages. Journal of general microbiology 1987; 
133:1111-26. 
32. Bradley DE. Shortening of Pseudomonas aeruginosa pili after RNA-phage adsorption. 
Journal of general microbiology 1972; 72:303-19. 
33. Rodriguez-Rojas A, Mena A, Martin S, Borrell N, Oliver A, Blazquez J. Inactivation of 
the hmgA gene of Pseudomonas aeruginosa leads to pyomelanin hyperproduction, stress 
resistance and increased persistence in chronic lung infection. Microbiology 2009; 
155:1050-7. 















34. Comolli JC, Hauser AR, Waite L, Whitchurch CB, Mattick JS, Engel JN. Pseudomonas 
aeruginosa gene products PilT and PilU are required for cytotoxicity in vitro and 
virulence in a mouse model of acute pneumonia. Infect Immun 1999; 67:3625-30. 
35. Clokie MRJ, Kropinski AM. Bacteriophages. Methods and Protocols. Volume 1: 
Isolation, Characterization, and Interactions. Humana Press ed. Vol. 1. 2009. 
36. Broskey NT, Daraspe J, Humbel BM, Amati F. Skeletal muscle mitochondrial and lipid 
droplet content assessed with standardized grid sizes for stereology. Journal of applied 
physiology (Bethesda, Md : 1985) 2013; 115:765-70. 
37. Taylor RD. Modification of the Brown and Brenn gram stain for the differential 
staining of gram-positive and gram-negative bacteria in tissue sections. Am J Clin Pathol 
1966; 46:472-4. 
38. Meyer F, Goesmann A, McHardy AC, et al. GenDB--an open source genome annotation 
system for prokaryote genomes. Nucleic Acids Res 2003; 31:2187-95. 
39. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. 
J Mol Biol 1990; 215:403-10. 
40. Alikhan NF, Petty NK, Ben Zakour NL, Beatson SA. BLAST Ring Image Generator 
(BRIG): simple prokaryote genome comparisons. BMC Genomics 2011; 12:402. 
41. Semmler AB, Whitchurch CB, Mattick JS. A re-examination of twitching motility in 
Pseudomonas aeruginosa. Microbiology 1999; 145 ( Pt 10):2863-73. 
42. Zhu ZX, Cong WT, Ni MW, et al. An improved silver stain for the visualization of 
lipopolysaccharides on polyacrylamide gels. Electrophoresis 2012; 33:1220-3. 
 
















Figure 1. Activity of phage cocktail PP1131 in in vitro fibrin clots. Clots were 
produced from rat plasma and infected with 108 CFU/ml of either phage-resistant P. 
aeruginosa strain PA7 (A) or phage-susceptible strain CHA (B). Clots were left 
untreated (solid lines) or exposed to 108 PFU/ml of PP1131 for 24 h at 37°C (dashed 
lines). Phage titers in non-infected clots (solid lines) and in PA7-infected or CHA-
infected clots (dashed lines) were determined 6 h and 24 h after exposure to the 
phage cocktail. Clots infected with strain PA7 lysed in spite of phage treatment (C), 
whereas those infected with phage-susceptible CHA and treated with phages 
remained intact (D). p-values were determined using the Mann Whitney test. 
 
Figure 2. Bactericidal synergism between phages and selected antibiotics. 
Bacterial killing by phage-antibiotic combinations was tested by using 108 PFU/ml of 
PP1131 with 2.5-times the MIC of ciprofloxacin (A) or meropenem (B) (MIC of 0.19 
µg/ml and 0.125 µg/ml, respectively). Each value represents the mean ± SD of 4 to 
16 independent clots. ABT; antibiotic. 
 
Figure 3. PK/PD and therapeutic efficacy of phage cocktail PP1131 and 
ciprofloxacin in rats with EE due to P. aeruginosa CHA. (A) Pharmacokinetics in 
the absence of infection of phage cocktail PP1131 in rat plasma after either a single 
i.v. bolus injection (1 ml of 1010 PFU/ml in 1 min, dashed line, Bolus) or the same 
amount of phages administered through continuous infusion (0.1 ml/h of 1010 PFU/ml 
over 24 h, solid line, C.I.). Each value represents the mean ± SD from 8 to 10 
individual animals. (B) Bacterial loads of infected vegetations after 6 h of phage 
treatment administered through continuous infusion or in single bolus, and treatment 















with ciprofloxacin alone or combined with phages. Each dot represents the vegetation 
of a single animal. The mode of injection and type of treatment are indicated at the 
top of columns (C.I.; continuous infusion. φ; phages). Statistical results are indicated 
at the bottom of columns (†: control versus all types of treatment, p < 0.0005. ‡: 
combination versus control and all the other types of treatments, p < 0.0001; results 
were compared by the Mann Whitney test). (C) Phage titers in vegetations measured 
in uninfected rats treated with bolus phage injection (control) or infected rats treated 
with the same regimens as in Fig 2.B (***, p < 0.0001 using the Mann Whitney test). 
(D) Correlation between the decrease in vegetation bacterial loads and the vegetation 
phage titers resulting from in situ phage amplification (continuous infusion and bolus 
injection pooled together; correlation value (r): -0.66, Pearson two tailed correlation 
test: p = 0.003). cip: ciprofloxacin. 
 
Figure 4.  Light microscopy and TEM of rat vegetations after 6 h phage therapy. 
(A) Semi-thin section (200 nm) of control vegetation infected with P. aeruginosa CHA 
stained using the modified Braun Brenn staining protocol [37]. Arrows indicate 
bacteria, stained in red (RBC: red blood cells). (B) TEM of ultra-thin sections (50 nm) 
of control vegetation infected with P. aeruginosa CHA positive-stained using uranium 
acetate and lead citrate. Arrows indicate bacteria. (C) Example of a negative staining 
of a myoviridae phage present in the cocktail; other phages morphotypes including 
podoviridae were also present. (D) TEM of vegetation infected by P. aeruginosa CHA 
and treated with the phage cocktail. Arrows indicate phage capsids inside lysed 
bacteria. 
 















Figure 5.  Cytokine quantification in rat plasma during EE. (A) Protocol of blood 
sampling for cytokine quantification. (B) Levels of IL-1β, IL-6 and TNF-α measured 
after 6 h of phage or antibiotherapy (treatment). Controls included rats 24 h after 
surgery (inoculum,T0), untreated but infected rats for 18 h or 24 h (bacteria T18 and 
T24), and uninfected rats receiving phage for 6 h (Phages T6). Each value represents 
the mean ± SEM from 4 to 10 individual animals (*, p = 0.03 and **, p = 0.005 using 
the Mann Whitney test). cip: ciprofloxacin. 
 
Figure 6. Infectivity of phage-resistant P. aeruginosa mutants in rats with 
catheter-induced vegetations. (A) Two phage resistant P. aeruginosa mutants, 24/2 
and 19/2, were isolated in vitro from fibrin clots and showed different phage 
resistance patterns. Lysis zones at the site of the phage deposits indicated phage-
sensitivity. The absence of lysis indicated phage-resistance. (B) The isolates’ 
infectivity was tested in rats with catheter-induced vegetations. Both variants showed 
a loss of infectivity (>40 % for 24/2 and >70 % for 19/) as compared to the parent 
strain CHA. p-values were determined using Fisher’s exact test. 
 
Figure 7. Characterization of phage-resistant P. aeruginosa mutants. The two phage 
resistant P. aeruginosa mutants, 24/2 and 19/2, isolated in vitro were further characterized 
regarding to genomic content and phenotypes. (A) Variant 24/2 displayed a 15 bp deletion in 
the pilT gene and variant 19/2 displayed a 362 Kb chromosomal deletion that encompassed 
the galU gene. (B) Impaired twitching motility resulting from the pilT alteration in variant 24/2, 
as compared to wild type PAO1 and parent CHA. (C) Impaired LPS synthesis resulting from 
the galU deletion in variant 19/2 with absence of O-antigen (O) and LPS core (C), as 
compared to parent CHA.  
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